Overview:

CRISPR (clustered regularly interspaced short palindromic repeat) and CRISPR-associated (Cas) proteins constitute the adaptive immune system in bacteria (1-2). This system has been redesigned to create an exemplary genome editing tool for RNA-based therapeutics development (3). Cas12 and Cas13 have collateral nucleotide cleavage activities and are widely used in CRISPR-based diagnostic platforms. FnCas12a from Francisella shows increased stability at >37◦C making it ideal for LAMP (loop-mediated isothermal amplification) (4).

Accession Number:

WP_003040289

Formulation:

Recombinant protein stored in 25mM Tris, 300mM NaCl pH7.5 50% glycerol 0.1mM TCEP.

References:

1. Horvath, P., et al. 2010. CRISPR/Cas, the immune system of bacteria and archaea. Science, 327(5962):167-170.

2. Morange, M. 2015. What history tells us XXXVII. CRISPR-Cas: The discovery of an immune system in prokaryotes. J. Biosci. 40(2):221-223.

3. Gier, R.A., et al. 2020. High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Nat. Commun. 11(1):1-9.

4. Mohanraju P, et al: Development of a Cas12a-Based Genome Editing Tool for Moderate Thermophiles. CRISPR J. Feb;4(1):82-91. 2021.